Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Aurobindo Pharma
Join Channel
Consolidated Standalone

Aurobindo Pharma

₹1257.1 -5.3 | 0.4%

Market Cap ₹73010 Cr.

Stock P/E 23.0

P/B 2.4

Current Price ₹1257.1

Book Value ₹ 531.7

Face Value 1

52W High ₹1592.6

Dividend Yield 0.36%

52W Low ₹ 959.1

Edit Ratio

Aurobindo Pharma Research see more...

Overview Inc. Year: 1986Industry: Pharmaceuticals & Drugs

Aurobindo Pharma Ltd is an India-based pharmaceutical company. The Company develops, manufactures and distributes generic pharmaceuticals, branded specially prescribed drugs and active pharmaceutical elements. Its product portfolio is spread over seven therapeutic/product areas comprising central nervous structures (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. It is engaged in growing a variety of oncology and hormonal products. It is growing topical as well as transdermal products within the dermatology therapeutic section. It is likewise developing approximately three depot injections based on the microsphere and nano-suspension structures. The Company is advertising its merchandise globally around 150 countries. The Company's subsidiaries consist of APL Healthcare Ltd, Auronext Pharma Private Ltd, Auro Peptides Ltd, APL Pharma Thai Ltd and Aurolife Pharma LLC, amongst others.

Read More..

Aurobindo Pharma Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Aurobindo Pharma Quarterly Results

#(Fig in Cr.) Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 6236 5739 6407 6473 6851 7219 7352 7580 7567 7796
Other Income 41 57 93 135 116 187 163 136 221 136
Total Income 6277 5797 6500 6608 6967 7406 7514 7716 7788 7932
Total Expenditure 5299 4949 5453 5471 5699 5846 5750 5907 5947 6230
Operating Profit 977 848 1047 1137 1268 1560 1764 1808 1841 1702
Interest 15 25 45 56 57 68 76 89 111 113
Depreciation 280 298 321 346 327 418 423 354 404 382
Exceptional Income / Expenses 0 0 0 0 -70 0 0 -122 0 0
Profit Before Tax 683 525 681 736 815 1075 1265 1243 1325 1207
Provision for Tax 159 113 189 224 242 324 322 323 406 391
Profit After Tax 524 412 492 512 573 751 943 920 920 817
Adjustments -4 -2 -0 -6 -2 6 -6 -11 -0 1
Profit After Adjustments 521 409 491 506 571 757 936 909 919 817
Adjusted Earnings Per Share 8.9 7 8.4 8.6 9.7 12.9 16 15.5 15.7 14.1

Aurobindo Pharma Profit & Loss

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 8100 12121 13795 14910 16463 19564 23099 24775 23455 24855 29002 30295
Other Income 22 97 204 116 102 155 192 381 323 291 557 656
Total Income 8121 12217 13998 15025 16565 19719 23290 25155 23778 25146 29559 30950
Total Expenditure 5966 9557 10607 11475 12691 15612 18234 19441 19071 21137 23159 23834
Operating Profit 2155 2660 3392 3550 3874 4107 5056 5714 4707 4009 6400 7115
Interest 310 160 257 67 78 263 305 74 49 140 290 389
Depreciation 313 333 392 428 558 668 967 1055 1127 1245 1522 1563
Exceptional Income / Expenses 0 0 0 0 0 -88 -26 2815 -128 0 -192 -122
Profit Before Tax 1533 2168 2744 3061 3241 3091 3743 7344 3373 2613 4380 5040
Provision for Tax 363 597 721 760 818 727 899 2010 726 685 1211 1442
Profit After Tax 1169 1571 2024 2301 2423 2365 2844 5334 2647 1928 3169 3600
Adjustments 4 5 2 0 0 0 1 1 1 -0 4 -16
Profit After Adjustments 1173 1576 2025 2302 2423 2365 2845 5335 2648 1928 3173 3581
Adjusted Earnings Per Share 20.1 27 34.6 39.3 41.4 40.4 48.6 91.1 45.2 32.9 54.2 61.3

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 17% 5% 8% 14%
Operating Profit CAGR 60% 4% 9% 11%
PAT CAGR 64% -16% 6% 10%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 18% 20% 22% 9%
ROE Average 11% 10% 15% 23%
ROCE Average 14% 12% 17% 21%

Aurobindo Pharma Balance Sheet

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 3750 5156 7287 9372 11680 13891 16825 21930 24576 26840 29843
Minority's Interest 26 26 3 2 2 2 0 -1 -2 12 8
Borrowings 1279 1361 743 181 451 180 0 168 249 619 2135
Other Non-Current Liabilities 215 230 -159 -79 143 178 555 639 654 248 -326
Total Current Liabilities 4220 6136 7840 6606 8666 12021 11385 10665 8156 11494 12199
Total Liabilities 9490 12910 15714 16082 20942 26271 28765 33401 33633 39213 43859
Fixed Assets 2722 3706 4180 4834 6521 8475 9396 9374 10532 11024 14493
Other Non-Current Assets 1137 905 1240 2042 2243 2464 2956 4204 4978 6643 5160
Total Current Assets 5631 8299 10294 9206 12178 15332 16413 19740 18044 21460 23772
Total Assets 9490 12910 15714 16082 20942 26271 28765 33401 33633 39213 43859

Aurobindo Pharma Cash Flow

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 203 148 404 743 318 1210 1876 2747 5330 4163 4392
Cash Flow from Operating Activities 646 1237 1420 3279 1955 1651 4381 3329 5016 2387 2435
Cash Flow from Investing Activities -819 -1398 -1445 -1787 -1927 -2903 -1568 599 -3212 -3978 -4256
Cash Flow from Financing Activities 118 93 365 -1915 864 1919 -1947 -1365 -2969 1814 800
Net Cash Inflow / Outflow -55 -68 340 -424 892 667 866 2563 -1164 223 -1021
Closing Cash & Cash Equivalent 148 461 744 320 1210 1876 2747 5330 4163 4392 3385

Aurobindo Pharma Ratios

# Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 20.12 26.98 34.61 39.28 41.36 40.36 48.56 91.05 45.2 32.9 54.16
CEPS(Rs) 25.41 32.6 41.28 46.57 50.88 51.76 65.03 109.05 64.41 54.14 80.06
DPS(Rs) 3 4.5 2.5 2.5 2.5 2.5 3 4 9 3 4.5
Book NAV/Share(Rs) 64.33 88.29 124.5 159.96 199.36 237.08 287.16 374.29 419.46 458.1 509.35
Core EBITDA Margin(%) 25.83 20.89 22.85 22.76 22.86 9.86 10.29 10.98 9.17 7.31 9.77
EBIT Margin(%) 22.31 18.97 21.5 20.73 20.11 8.36 8.57 15.27 7.16 5.41 7.81
Pre Tax Margin(%) 18.56 17.66 19.67 20.28 19.64 7.71 7.92 15.11 7.05 5.14 7.33
PAT Margin (%) 14.15 12.8 14.5 15.25 14.68 5.9 6.02 10.98 5.54 3.79 5.3
Cash Profit Margin (%) 17.94 15.51 17.31 18.08 18.07 7.56 8.06 13.15 7.89 6.24 7.85
ROA(%) 13.95 14.03 14.14 14.47 13.09 10.02 10.33 17.16 7.9 5.29 7.63
ROE(%) 36.79 35.29 32.53 27.63 23.02 18.49 18.52 27.53 11.38 7.5 11.18
ROCE(%) 27.18 27.18 27.36 24.96 22.74 17.98 18.72 30.1 12.71 9.39 13.76
Receivable days 93.55 91.84 106.53 89.16 64.66 29.56 29.85 29.37 28.69 30.42 28.34
Inventory Days 94.82 88.91 100.27 101.43 112.7 59.64 57.72 62.82 63.29 57.65 55.92
Payable days 128.98 121.75 146.6 142.39 135.78 113.97 107.32 111.03 108.6 117.74 133.88
PER(x) 12.7 22.61 21.53 17.19 13.47 19.47 8.51 9.68 14.8 15.75 20.12
Price/Book(x) 3.97 6.91 5.98 4.22 2.8 3.32 1.44 2.36 1.59 1.13 2.14
Dividend Yield(%) 0.59 0.37 0.34 0.37 0.45 0.32 0.73 0.45 1.35 0.58 0.41
EV/Net Sales(x) 2.28 3.27 3.47 2.84 2.2 2.61 1.17 2.06 1.59 1.17 2.2
EV/Core EBITDA(x) 8.58 14.89 14.1 11.95 9.33 12.43 5.32 8.95 7.94 7.27 9.98
Net Sales Growth(%) 38.33 49.64 13.81 8.08 10.42 18.83 18.07 7.26 -5.32 5.97 16.68
EBIT Growth(%) 187.58 26.32 28.92 4.22 6.12 1.06 20.8 83.25 -53.88 -19.54 69.62
PAT Growth(%) 301.19 34.4 28.79 13.72 5.29 -2.41 20.4 87.57 -50.37 -27.18 64.4
EPS Growth(%) 298.71 34.12 28.25 13.52 5.28 -2.41 20.32 87.51 -50.36 -27.21 64.62
Debt/Equity(x) 1.01 0.86 0.69 0.36 0.41 0.5 0.33 0.23 0.1 0.18 0.21
Current Ratio(x) 1.33 1.35 1.31 1.39 1.41 1.28 1.44 1.85 2.21 1.87 1.95
Quick Ratio(x) 0.77 0.76 0.8 0.74 0.73 0.67 0.77 1 1.29 1.13 1.14
Interest Cover(x) 5.94 14.56 11.69 46.88 42.7 12.77 13.27 99.58 70.34 19.6 16.12
Total Debt/Mcap(x) 0.25 0.12 0.12 0.09 0.15 0.15 0.23 0.1 0.06 0.16 0.1

Aurobindo Pharma Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 51.83 51.83 51.83 51.83 51.83 51.83 51.83 51.83 51.8 51.82
FII 20.71 21.4 22.31 23.02 24.13 22.45 20.72 18.02 16.73 16.59
DII 17.3 16.57 14.9 15.09 15.73 18.29 20.6 23.28 24.77 25.13
Public 10.15 10.2 10.96 10.05 8.31 7.42 6.85 6.87 6.7 6.46
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company is almost debt free.

Cons

  • Company has a low return on equity of 10% over the last 3 years.
  • Debtor days have increased from 117.74 to 133.88days.
  • The company has delivered a poor profit growth of 6% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Aurobindo Pharma News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!